Northwest Biotherapeutics Inc 8-K Filing
Ticker: NWBO · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1072379
| Field | Detail |
|---|---|
| Company | Northwest Biotherapeutics Inc (NWBO) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $5 million, $0.29 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Northwest Biotherapeutics Inc (ticker: NWBO) to the SEC on Nov 20, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by); $5 million (ber 14, 2025 the Company entered into a $5 million convertible Promissory Note financing (); $0.29 (th unless the conversion price is above $0.29. Item 2.03. Creation of a Direct Finan).
How long is this filing?
Northwest Biotherapeutics Inc's 8-K filing is 2 pages with approximately 551 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-20 16:26:03
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
- $5 million — ber 14, 2025 the Company entered into a $5 million convertible Promissory Note financing (
- $0.29 — th unless the conversion price is above $0.29. Item 2.03. Creation of a Direct Finan
Filing Documents
- tm2531842d1_8k.htm (8-K) — 23KB
- 0001104659-25-114627.txt ( ) — 182KB
- nwbo-20251114.xsd (EX-101.SCH) — 3KB
- nwbo-20251114_lab.xml (EX-101.LAB) — 33KB
- nwbo-20251114_pre.xml (EX-101.PRE) — 22KB
- tm2531842d1_8k_htm.xml (XML) — 4KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. Loan Entered Into On November 14, 2025 the Company entered into a $5 million convertible Promissory Note financing (the "Note") with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP ("Yorkville"). The Company plans to use the financing proceeds for some of the construction and equipment costs for the first Grade C manufacturing suite in its Sawston, UK facility, as well as for ongoing Company operations. The term of the Note is 12 months. No payments are due until maturity. The Note carries an Original Issue Discount of five percent but no interest. The Note includes customary default provisions. During the term of the Note, it is convertible at the option of the holder, at a small discount to the then prevailing market price. The amounts of such conversions are limited to approximately one fifth (1/5) of the overall Note amount in any given calendar month unless the conversion price is above $0.29.
03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: November 20, 2025 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman